Cigna: Deeply Undervalued With Double-Digit EPS Growth Ahead (NYSE:CI)

seekingalpha.com · 2026-10-01

Cigna is rated a 'Strong Buy' for its compelling value, robust earnings growth, and capital returns at a forward P/E of 8.9x. Learn more about CI stock here.

TickrTrends take: Cigna trades at a valuation that TickrTrends currently classifies as undervalued within the Healthcare sector, positioning the stock for potential appreciation if earnings growth materializes as anticipated. An investor focused on valuation metrics should monitor whether the company delivers on the double-digit earnings per share growth outlined in the headline, as actual execution would reinforce the undervalued assessment. The combination of current price levels and projected earnings expansion creates a scenario where valuation multiples could compress or the stock price could rise to reflect normalized market pricing.

Read the full story at seekingalpha.com →